ライフサイエンスコーパス: empagliflozin

1 apagliflozin) and EMPEROR-Reduced (assessing empagliflozin).

2 fore and 48 h and 14 days after the start of empagliflozin.

3 after more chronic (14 days) treatment with empagliflozin.

4 or protein expression was also observed with empagliflozin.

5 intra-renal renin activity was enhanced with empagliflozin.

6 the likelihood of response to treatment with empagliflozin.

7 val: -0.14 to 0.32 l/min/m(2); p = 0.448) by empagliflozin.

8 arameters, and plasma NO were not altered by empagliflozin.

9 r hypotension occurred among those receiving empagliflozin.

10 ere [16%] and 11 serious [12%]), 86 (88%) on empagliflozin 10 mg (six severe [6%] and six serious [6%

11 k 24 were -0.52% (95% CI -0.72 to -0.32) for empagliflozin 10 mg and -0.68% (-0.88 to -0.49) for empa

12 c HFrEF patients (n = 84) were randomized to empagliflozin 10 mg daily or placebo for 6 months.

13 mized, placebo-controlled crossover study of empagliflozin 10 mg daily versus placebo.

14 alized for AHF were randomized 1:1 to either empagliflozin 10 mg once daily or placebo for 90 days.

15 Patients were randomly assigned 1:1 to empagliflozin 10 mg once daily or placebo, stratified by

16 0) were randomly assigned (1:1:1) to receive empagliflozin 10 mg or 25 mg or placebo once daily for 5

17 s and Results Individuals were randomized to empagliflozin 10 mg, 25 mg, or placebo.

18 stablished cardiovascular disease (1:1:1) to empagliflozin 10 mg, empagliflozin 25 mg, or placebo in

19 (-2) at screening were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo onc

20 on fraction <=40% were randomized to receive empagliflozin (10 mg daily) or placebo in addition to re

21 0% to double-blind treatment with placebo or empagliflozin (10 mg once daily), in addition to recomme

22 The participants were randomized to empagliflozin (10 mg/day, n=49) or placebo (n=48) for 6

23 ter 3 weeks, rats were randomized to receive empagliflozin (10 mg/kg per day) or water (vehicle) for

24 ure rat (mRen27/tetO-shIR) were treated with empagliflozin (10 mg/kg/d) or vehicle for 4 weeks.

25 mong 744 914 eligible patients, 28 075 began empagliflozin (15 976 [56.9%]) or dapagliflozin (12 099

26 ratio of relative change from baseline with empagliflozin: -22%, 95% CI -32 to -11; p=0.0003) or mac

27 [8%] and 23 serious [12%]) and 156 (83%) on empagliflozin 25 mg (18 severe [10%] and 22 serious [12%

28 flozin 10 mg and -0.68% (-0.88 to -0.49) for empagliflozin 25 mg (both p<0.0001).

29 e [6%] and six serious [6%]) and 78 (80%) on empagliflozin 25 mg (eight severe [8%] and seven serious

30 c at week 24 was -0.42% (-0.56 to -0.28) for empagliflozin 25 mg (p<0.0001).

31 regular loop diuretic who were randomized to empagliflozin 25 mg once daily or placebo for 6 weeks wi

32 374) were randomly assigned (1:1) to receive empagliflozin 25 mg or placebo for 52 weeks.

33 dium glucose cotransporter 2 inhibition with empagliflozin 25 mg QD on renal hyperfiltration in subje

34 ular disease (1:1:1) to empagliflozin 10 mg, empagliflozin 25 mg, or placebo in addition to standard

35 e randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily in addition t

36 stration of either 1) placebo, 2) the SGLT2i empagliflozin (25 mg), 3) the glucagon receptor antagoni

37 le dose, and following 4-week treatment with empagliflozin (25 mg).

38 e (NFG) and eight subjects with IFG received empagliflozin (25 mg/day) for 2 weeks.

39 validated, allowing sensitive estimation of empagliflozin (25-600 ng mL(-1)) in human plasma using d

40 Compared with vehicle, empagliflozin 30 mg/kg/day for 2 weeks significantly red

41 es in patients with diabetes with the use of empagliflozin, a member of this new class of drugs.

42 ar disease with the antihyperglycemic agent, empagliflozin, a sodium glucose cotransporter 2 (SGLT2)

43 Empagliflozin, a sodium-glucose cotransporter 2 inhibito

44 In the EMPA-REG OUTCOME trial, empagliflozin, a sodium-glucose cotransporter 2 inhibito

45 pe 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose cotransporter-2 inhibito

46 To determine whether glucose lowering by empagliflozin accelerates atherosclerosis regression in

47 Canagliflozin, dapagliflozin, and empagliflozin accounted for 53%, 42%, and 5% of the tota

48 In both groups, empagliflozin administration raised EGP, lowered TGD, an

49 Empagliflozin administration to nondiabetic HFrEF patien

50 considered the pharmacokinetic evaluation of empagliflozin after administration to Egyptian volunteer

51 Canagliflozin, dapagliflozin, and empagliflozin, all recently approved for treatment of ty

52 In the empagliflozin-allocated group, there was significant low

53 Empagliflozin also caused significant reductions in body

54 Unexpectedly, empagliflozin also reduced intestinal cholesterol absorp

55 Interestingly, empagliflozin also reduces intestinal cholesterol absorp

56 Empagliflozin ameliorates adverse cardiac remodeling and

57 to determine the long-term renal effects of empagliflozin, an analysis that was a prespecified compo

58 The effects of empagliflozin, an inhibitor of sodium-glucose cotranspor

59 repurpose the widely used antidiabetic drug empagliflozin, an inhibitor of the renal glucose cotrans

60 tration of the novel glucose lowering agent, empagliflozin, an SGLT2 inhibitor which targets the kidn

61 819 individuals who initiated treatment with empagliflozin and 17 464 with dapagliflozin were include

62 al of 3260 patients were assigned to receive empagliflozin and 3262 to receive placebo.

63 MPEROR-Preserved trials (9718 patients; 4860 empagliflozin and 4858 placebo), and patients were group

64 -glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower

65 The effects of empagliflozin and dapagliflozin on hospitalisations for

66 led trial (the SUGAR-DM-HF trial [Studies of Empagliflozin and Its Cardiovascular, Renal and Metaboli

67 Empagliflozin and LY2409021 individually lowered fasting

68 transition pairs of m/z 449.01 to 371.21 for empagliflozin and m/z 407.00 to 328.81 for dapagliflozin

69 pitalization for heart failure in the pooled empagliflozin and placebo groups were analyzed in subgro

70 s were studied after 4 weeks' treatment with empagliflozin and placebo in a randomized, double-blind,

71 patients were randomized (95 each receiving empagliflozin and placebo), with a mean (SD) age of 64 (

72 .6 g/m(2) and 0.01 g/m(2) for those assigned empagliflozin and placebo, respectively (adjusted differ

73 consistent with the known safety profile of empagliflozin and were similar in the two trial groups.

74 me was for use of dapagliflozin, with 5% for empagliflozin, and 1% for canagliflozin.

75 r dapagliflozin, 2.52 (CI, 1.23 to 5.14) for empagliflozin, and 3.58 (CI, 2.13 to 6.03) for canaglifl

76 the trial, 43 (49%) received treatment with empagliflozin, and 44 (51%) received placebo.

77 Oral semaglutide, empagliflozin, and liraglutide also reduced cardiovascul

78 ical trials of canagliflozin, dapagliflozin, empagliflozin, and sotagliflozin in patients with type 1

79 /-17.9 g/m(2) and 63.8+/-14.0 g/m(2) for the empagliflozin- and placebo-assigned groups, respectively

80 In addition, in the heart, empagliflozin appears to inhibit sodium-hydrogen exchang

81 We assessed the efficacy and safety of empagliflozin as an add-on treatment in patients with ty

82 risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rat

83 out baseline cardiovascular disease, and for empagliflozin at both the 10- and 25-mg daily doses; ana

84 m(2) of body-surface area to receive either empagliflozin (at a dose of 10 mg or 25 mg) or placebo o

85 the sodium glucose cotransporter 2 inhibitor empagliflozin attenuated renal hyperfiltration in subjec

86 In this model, blood glucose lowering with empagliflozin attenuated some molecular and histological

87 In male db/db mice, a 10-week treatment with empagliflozin attenuated the diabetes-induced upregulati

88 ar filtration rate stabilized over time with empagliflozin but gradually declined with placebo.

89 These data suggest that empagliflozin, by switching energy metabolism from carbo

90 rters (eg, dapagliflozin, canagliflozin, and empagliflozin) can slow the rate of intestinal glucose a

91 Empagliflozin cardiac benefits in the EMPA-REG OUTCOME (

92 The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type

93 Background In EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type

94 in cardiac benefits in the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type

95 cular disease in the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type

96 The Empagliflozin, Cardiovascular Outcomes, and Mortality in

97 In a landmark trial called Empagliflozin, Cardiovascular Outcomes, and Mortality in

98 inical outcomes, the EMPA-REG OUTCOME trial (Empagliflozin, Cardiovascular Outcomes, and Mortality in

99 observed in the EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Typ

100 The EMPA-REG OUTCOME trial ([Empagliflozin] Cardiovascular Outcome Event Trial in Typ

101 In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Typ

102 Empagliflozin caused 50 +/- 4 and 45 +/- 4 g glucosuria

103 Empagliflozin caused a nonsignificant increase in fracti

104 Compared with placebo, empagliflozin caused a significant increase in 24-hour u

105 Empagliflozin caused a significant increase in 24-hour u

106 We sought to determine if empagliflozin causes a decrease in left ventricular (LV)

107 Empagliflozin causes significant natriuresis, particular

108 The EMPRISE (Empagliflozin Comparative Effectiveness and Safety) stud

109 EMPA-REG OUTCOME support the hypothesis that empagliflozin could reduce the risk of clinically releva

110 Addition of empagliflozin daily to standard medical treatment of acu

111 otransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are now

112 Compared with sitagliptin, the initiation of empagliflozin decreased the risk of HHF-specific by 50%

113 Urinary glucose excretion with empagliflozin decreases with declining renal function, r

114 Empagliflozin did not affect myocardial free fatty acids

115 ct NHE3 inhibition using the SGLT2 inhibitor empagliflozin did not affect urinary calcium and phospha

116 At 6 weeks, empagliflozin did not cause a significant change in 24-h

117 Empagliflozin did not change myocardial oxygen consumpti

118 Across these 3 end points, the effect of empagliflozin did not differ in patients with prediabete

119 acute myocardial infarction, treatment with empagliflozin did not lead to a significantly lower risk

120 Empagliflozin did not lower HbA1c in patients with predi

121 dium-glucose cotransporter 2 inhibition with empagliflozin did not result in a meaningful reduction i

122 prandial PG excursion, which was annulled by empagliflozin during their combination (empagliflozin +

123 criteria, assessing three SGLT2 inhibitors: empagliflozin (EMPA-REG OUTCOME), canagliflozin (CANVAS

124 Empagliflozin enhanced beta-cell function only in subjec

125 art failure hospitalizations associated with empagliflozin, even though, by design, the hemoglobin A1

126 Among patients with stable HFrEF, empagliflozin for 12 weeks reduced PCWP compared with pl

127 itiated in 13 of 4687 patients (0.3%) in the empagliflozin group and in 14 of 2333 patients (0.6%) in

128 n 490 of 4687 patients (10.5%) in the pooled empagliflozin group and in 282 of 2333 patients (12.1%)

129 urred in 525 of 4124 patients (12.7%) in the empagliflozin group and in 388 of 2061 (18.8%) in the pl

130 ccurred in 70 of 4645 patients (1.5%) in the empagliflozin group and in 60 of 2323 (2.6%) in the plac

131 compared with placebo, fewer patients in the empagliflozin group reported intensification of diuretic

132 chemic myocardial injury in both groups, the empagliflozin group showed amelioration of adverse remod

133 myocardial infarction or stroke, but in the empagliflozin group there were significantly lower rates

134 -creatinine ratio (UACR) data for the pooled empagliflozin group versus placebo according to albuminu

135 r nonfatal stroke, as analyzed in the pooled empagliflozin group versus the placebo group.

136 Among MRA users at baseline, patients in the empagliflozin group were 22% less likely than those in t

137 ng MRA nonusers at baseline, patients in the empagliflozin group were 35% less likely than those in t

138 %) in the placebo group (hazard ratio in the empagliflozin group, 0.61; 95% confidence interval, 0.53

139 %) in the placebo group (hazard ratio in the empagliflozin group, 0.86; 95.02% confidence interval, 0

140 7-15.7 mL, P = 0.0015), respectively, in the empagliflozin group, compared with placebo.

141 epresenting a 55% lower relative risk in the empagliflozin group.

142 62 (9.9%) patients had HF in the placebo and empagliflozin groups, respectively.

143 In EMPEROR-Reduced, empagliflozin had a beneficial effect on the key efficac

144 d with fluid restriction, those who received empagliflozin had a larger increase in plasma sodium lev

145 Patients treated with empagliflozin had a significantly higher increase of med

146 Patients who received empagliflozin had significant improvements in peak O(2)

147 260 assigned to placebo and 509 assigned to empagliflozin) had macroalbuminuria.

148 675 assigned to placebo and 1338 assigned to empagliflozin) had microalbuminuria, and 769 (11%; 260 a

149 382 assigned to placebo and 2789 assigned to empagliflozin) had normoalbuminuria, 2013 (29%; 675 assi

150 ith the lowest risk of glaucoma, followed by empagliflozin (HR 0.727, 95% CI 0.696, 0.759), dapaglifl

151 t-years of follow-up), and it was reduced by empagliflozin (HR, 0.70; 95% CI, 0.63-0.78; P<0.0001).

152 Empagliflozin improved clinical outcomes and reduced mor

153 In summary, plasma glucose lowering by empagliflozin improves plaque regression in diabetic mic

154 Off-label use of empagliflozin in 4 GSD-Ib patients with incomplete respo

155 eath, suggesting that the benefits seen with empagliflozin in a randomized trial may be a class effec

156 The reductions in UACR were maintained with empagliflozin in all three groups compared with placebo

157 TmG was further reduced by empagliflozin in both groups on day 14 (by 65 +/- 5 and

158 ssess the diuretic and natriuretic effect of empagliflozin in combination with loop diuretics.

159 the hyperglycemic clamp was not affected by empagliflozin in either IFG or NFG.

160 ly, none of these parameters were changed by empagliflozin in fed conditions.

161 milar characteristics as participants of the Empagliflozin in Heart Failure With a Preserved Ejection

162 Cardiovascular and renal outcomes with empagliflozin in heart failure.

163 orter 2 (SGLT2) inhibitors dapagliflozin and empagliflozin in HFrEF patients.

164 lure]) to investigate the cardiac effects of empagliflozin in patients in New York Heart Association

165 e prespecified a comparison of the effect of empagliflozin in patients with and without diabetes.

166 The adverse event profile of empagliflozin in patients with eGFR <60 mL.min(-1).1.73

167 The adverse-event profile of empagliflozin in patients with impaired kidney function

168 -glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus

169 ion of renal sodium-glucose cotransport with empagliflozin in subjects with IFG and NFG produces comp

170 n was attenuated by -33 mL/min/1.73m(2) with empagliflozin in T1D-H, (GFR 172+/-23-139+/-25 mL/min/1.

171 (Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Wit

172 including dapagliflozin, canagliflozin, and empagliflozin, increase glucose excretion and lower bloo

173 Empagliflozin increased myocardial ATP content and enhan

174 The mechanisms by which the SGLT2 inhibitor empagliflozin increases LDL cholesterol levels were inve

175 (Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity?

176 In patients with type 2 diabetes, empagliflozin-induced glycosuria improved beta cell func

177 demonstrated the largest treatment effect of empagliflozin: insulin-like growth factor-binding protei

178 abetes, initial therapy with finerenone plus empagliflozin led to a greater reduction in the urinary

179 renal benefit, the antihyperglycaemic drugs empagliflozin, liraglutide, and semaglutide-the latter b

180 und treatment (21 trials), oral semaglutide, empagliflozin, liraglutide, extended-release exenatide,

181 Empagliflozin lowered blood sugar levels compared to veh

182 d by empagliflozin during their combination (empagliflozin + LY2409021).

183 st LY2409021 (300 mg), or 4) the combination empagliflozin + LY2409021.

184 he sodium-glucose cotransporter 2 inhibitor, empagliflozin, markedly and rapidly reduced CV death and

185 After treatment with empagliflozin, median serum sodium level rose to 134 mmo

186 etion of sodium increased significantly with empagliflozin monotherapy versus placebo (fractional exc

187 beyond therapy with metformin, ramipril, and empagliflozin (MRE).

188 After 14 days of empagliflozin, natriuresis waned due to increased reabso

189 Patients were assigned to empagliflozin of 10 mg or matching placebo once daily on

190 port the short-term and long-term effects of empagliflozin on albuminuria in patients with type 2 dia

191 We aim to study the effect of empagliflozin on cardiovascular and kidney outcomes acro

192 of sodium-glucose cotransporter-2 inhibitor empagliflozin on central hemodynamics in patients with H

193 We investigated the effects of empagliflozin on clinical outcomes in patients with type

194 Post hoc, we evaluated empagliflozin on kidney outcomes in patients with or wit

195 se of this study was to assess the effect of empagliflozin on left ventricular (LV) function and volu

196 sodium-glucose cotransporter inhibition with empagliflozin on the fasting plasma glucose (FPG) concen

197 The effect of empagliflozin on the primary composite outcome and key s

198 did not significantly modify the benefits of empagliflozin on the primary outcome (P-interaction=0.40

199 Effects of empagliflozin on these outcomes were consistent across c

200 did not differ with respect to the effect of empagliflozin on total hospitalizations for heart failur

201 support short-term and long-term benefits of empagliflozin on urinary albumin excretion, irrespective

202 tched pairs initiating treatment with either empagliflozin or liraglutide) were included in cohort 1,

203 losclerosis, however, were not improved with empagliflozin or metformin, and plasma and intra-renal r

204 Animals were randomized to empagliflozin or placebo for 2 months.

205 of <1000 ml/24 h, a once-daily dose of oral empagliflozin or placebo for 4 days.

206 signed patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily.

207 Of 3730 patients who were randomized to empagliflozin or placebo, 1978 (53%) had CKD.

208 rt of T2D patients >=18 years old initiating empagliflozin or sitagliptin from August 2014 through Se

209 tched pairs initiating treatment with either empagliflozin or sitagliptin) were included in cohort 2.

210 dentified 16,443 patient pairs who initiated empagliflozin or sitagliptin.

211 These mice then received either empagliflozin or vehicle for three weeks.

212 o any significant extent with dapagliflozin, empagliflozin, or phlorizin.

213 (EMPagliflozin outcomE tRial in Patients With chrOnic hea

214 n Fraction [EMPEROR-Preserved], NCT03057951; EMPagliflozin outcomE tRial in Patients With chrOnic hea

215 (EMPagliflozin outcomE tRial in Patients With chrOnic hea

216 (Empagliflozin Outcome Trial in Patients With Chronic Hea

217 (Empagliflozin Outcome Trial in Patients With Chronic Hea

218 (Empagliflozin Outcome Trial in Patients With Chronic Hea

219 In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Hea

220 In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Hea

221 At 14 days, the natriuretic effect of empagliflozin persisted, resulting in a reduction in blo

222 ealth care system was constructed to compare empagliflozin plus standard care to standard care alone

223 EMPA-REG Outcomes], long-term treatment with empagliflozin prevented fatal and nonfatal heart failure

224 um glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary gluc

225 he sodium-glucose co-transporter 2 inhibitor empagliflozin provides cardiac protection.

226 jected intravenously by 20%, indicating that empagliflozin raises LDL levels through reduced cataboli

227 m-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin reduced albuminuria in patients with type

228 art Failure With Reduced Ejection Fraction), empagliflozin reduced cardiovascular death or heart fail

229 s with type 2 diabetes and stage 2 or 3 CKD, empagliflozin reduced HbA1c and was well tolerated.

230 Empagliflozin reduced hemoglobin A1c significantly in bo

231 Empagliflozin reduced LV end-diastolic volume index by 8

232 In comparison with placebo, empagliflozin reduced LV end-systolic volume index by 6.

233 The sodium-glucose cotransporter 2 inhibitor empagliflozin reduced LV volumes in patients with HFrEF

234 Empagliflozin reduced postprandial PG through increased

235 Empagliflozin reduced resting MBF by 13% (P < 0.01), but

236 In the HF group, empagliflozin reduced risk of incident or worsening neph

237 Empagliflozin reduced the combined risk of death, hospit

238 Empagliflozin reduced the plasma glucose concentration t

239 Empagliflozin reduced the primary outcome and total HF h

240 art failure and a reduced ejection fraction, empagliflozin reduced the risk and total number of inpat

241 s with prevalent kidney disease at baseline, empagliflozin reduced the risk of cardiovascular death b

242 Empagliflozin reduced the risk of the primary outcome in

243 ascular disease, in comparison with placebo, empagliflozin reduced the risks of 3-point major adverse

244 Empagliflozin reduced the total number of heart failure

245 Empagliflozin reduces blood glucose levels via inhibitio

246 sodium-glucose transporter-2 inhibition with empagliflozin reduces both TmG and threshold for glucose

247 Empagliflozin reduces the risk of cardiovascular death o

248 The hypothesis was that empagliflozin's cardiac benefits are mediated by switchi

249 fectiveness and Safety) study aims to assess empagliflozin's effectiveness, safety, and healthcare ut

250 he sodium-glucose-co-transporter 2-inhibitor empagliflozin seem to be especially advantageous with re

251 Empagliflozin showed beneficial effects on cardiovascula

252 art Failure With Reduced Ejection Fraction), empagliflozin significantly improved cardiovascular and

253 Empagliflozin significantly reduced the catabolism of (3

254 Trial in Type 2 Diabetes Mellitus Patients) empagliflozin significantly reduced the risk of cardiova

255 Empagliflozin slowed the slope of eGFR decline by 1.11 (

256 Empagliflozin switches myocardial fuel utilization away

257 nts with genital infections was greater with empagliflozin than placebo in all subgroups by UACR stat

258 efficacy results were driven by findings for empagliflozin (the only SGLT2 inhibitor for which data f

259 Among patients receiving empagliflozin, there was an increased rate of genital in

260 tion in cardiovascular mortality would bring empagliflozin to $180 000 per QALY gained, the threshold

261 d be considered with administration of 25 mg empagliflozin to Egyptian population.

262 Atherosclerotic plaques in the empagliflozin treated mice were significantly smaller, s

263 ascular wall were significantly decreased in empagliflozin-treated mice.

264 ncreased risk of mycotic genital infections, empagliflozin-treated patients had fewer serious adverse

265 Empagliflozin-treated pigs did not consume glucose (redu

266 Both single-dose and chronic empagliflozin treatment caused glycosuria during fasting

267 Empagliflozin treatment for 48 h reduced the TmG in both

268 hypertension and investigated the effect of empagliflozin treatment to test the hypothesis if empagl

269 apagliflozin) and EMPEROR-Reduced (assessing empagliflozin) trials showed that sodium-glucose co-tran

270 ummary, the glucose-lowering SGLT2 inhibitor empagliflozin, used for type 2 diabetes, was successfull

271 ined by 1.6+/-0.4 in patients withdrawn from empagliflozin versus placebo (P<0.0001).

272 dian of 34 or 35 days, UACR was lower in the empagliflozin versus placebo group in those with baselin

273 urohormones were similar (P<0.34) during the empagliflozin versus placebo period.

274 cardiovascular disease randomly assigned to empagliflozin versus placebo reported a 14% reduction in

275 y cardiovascular outcomes and mortality with empagliflozin versus placebo were consistent across the

276 E and hospitalization for heart failure with empagliflozin versus placebo were consistent in patients

277 ravenous treatment (415 versus 519 patients; empagliflozin versus placebo, respectively; hazard ratio

278 he risk of HHF among T2D patients initiating empagliflozin versus sitagliptin, a dipeptidyl peptidase

279 0- and 25-mg daily doses; analyses comparing empagliflozin versus the dipeptidyl peptidase-4 inhibito

280 Absolute benefits of empagliflozin vs sitagliptin were larger in patients wit

281 edian (95% confidence interval) differences, empagliflozin vs. placebo, at Week 12 were -4.0 m (-16.0

282 (-25.1 +/- 26.0 ml vs. -1.5 +/- 25.4 ml for empagliflozin vs. placebo, respectively; p < 0.001) and

283 ss (-17.8 +/- 31.9 g vs. 4.1 +/- 13.4 g, for empagliflozin vs. placebo, respectively; p < 0.001) and

284 2.6 ml/min/kg vs. -0.5 +/- 1.9 ml/min/kg for empagliflozin vs. placebo, respectively; p = 0.017), oxy

285 (-26.6 +/- 20.5 ml vs. -0.5 +/- 21.9 ml for empagliflozin vs. placebo; p < 0.001).

286 This finding indicates that empagliflozin warrants further study as a treatment for

287 mean ratio of UACR change from baseline with empagliflozin was -7% (95% CI -12 to -2; p=0.013) in pat

288 compared with sitagliptin, the initiation of empagliflozin was associated with a decreased risk of HH

289 Across subgroups, empagliflozin was associated with a lower risk of the mo

290 Empagliflozin was associated with a significant reductio

291 Empagliflozin was associated with reductions in LV mass

292 Empagliflozin was associated with remarkable reduction o

293 ronary artery disease, SGLT2 inhibition with empagliflozin was associated with significant reduction

294 type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of

295 Oral empagliflozin was rapidly absorbed as evidenced by a 27-

296 Empagliflozin was well tolerated in CKD patients.

297 Additionally, patients assigned to empagliflozin were 20% to 40% more likely to experience

298 Patients treated with empagliflozin were more likely to experience a sustained

299 atic levels were further reduced by 84% with empagliflozin, while 3-hydroxy-3-methylglutaryl-CoA redu

300 liflozin treatment to test the hypothesis if empagliflozin will be protective in a heart failure mode